Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of [18F]AlF-PSMA-N5 and [18F]F-DCFPyL in Prostate Cancer
NCT06756334Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]AlF-PSMA-N5 in prostate cancer (PCa), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Standard Uptake Value at 30 days. Started Dec 2024; status: recruiting.
02
Drugs
[18F]AlF-PSMA-N5
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06756334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756334.